论文部分内容阅读
上个月食品与药物管理局最后批准了静脉用氨联吡啶酮(Winthrop-Breon商品名Inocor)短期治疗充血性心力衰竭病人。氨联吡啶酮不同于洋地黄糖甙或儿茶酚胺,它是具有增强收缩力活性和血管扩张剂特性的第一种新型双吡啶衍生物。 Winthrop-Breon实验室医疗主任Glenda Tredway医师说,对于难治性心力衰竭的病
Last month, the Food and Drug Administration finally approved the short-term treatment of patients with congestive heart failure with intravenous dipyridamone (Winthrop-Breon trade name Inocor). Ampicidin, unlike digoxygenin or catecholamines, is the first novel bipyridine derivative with synergistic activity and vasodilator properties. Glenda Tredway, MD, director of medical research at Winthrop-Breon Laboratory, said that for patients with refractory heart failure